Clinical trial
Low-Dose Spironolactone and Changes in Blood Pressure, Heart Rate Variability, and Inflammatory and Cardiac Biomarkers in Hemodialysis Patients With Resistant Hypertension: A Single-Arm Pre-Post Study
NCT07888504 is registered in ClinicalTrials.gov with Universitas Sebelas Maret as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Low-Dose Spironolactone and Changes in Blood Pressure, Heart Rate Variability, and Inflammatory and Cardiac Biomarkers in Hemodialysis Patients With Resistant Hypertension: A Single-Arm Pre-Post Study
- Lead sponsor
- Universitas Sebelas Maret
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- August 20, 2024
- Completion date
- October 31, 2024
- Enrollment
- 21 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hemodialysis, kidney failure, chronic, resistant hypertension
Arms
As registered; 1 arm.
-
Spironolactone 12.5 mg
Oral spironolactone 12.5 mg once daily for 6 weeks, added to the existing antihypertensive regimen.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Change in systolic blood pressure
Office systolic blood pressure (mmHg). Change = week-6 value minus baseline value.
-
Change in diastolic blood pressure
Office diastolic blood pressure (mmHg). Change = week-6 value minus baseline value.
Lead sponsor's other trials
Universitas Sebelas Maret, most recent start first.
+24 more trials
Similar trials
Same condition (Kidney Failure, Chronic) and phase, most recent start first.
+230 more trials See the condition page